Evidence map›Paper›PMID 40577077›Full record

ArticleFuture oncology (London, England)2025

Precision-medicine management recommendations for advanced non-small cell lung cancer: expert consensus.

Hampig Raphael Kourie, Mounir Ahmed Bachouchi, Malika Makhlouf Gamaz, Emad Anwar Dawoud, Zine-Charaf Mohamed Amir, Hicham Abdelmalek El Attar, Samah Soud Alrehaily, Joseph Fadi Zouein, Nabih Naim, Ameer Dhahir Hameedi and 8 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hampig Raphael KourieHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Mounir Ahmed BachouchiOncology Department, Clinique d'oncologie 16 Novembre, Rabat, Morocco.
Malika Makhlouf GamazDepartment of Medical Oncology, Center Pierre Marie Curie, Algiers, Algeria.
Emad Anwar DawoudDepartment of Oncology, Tawam Hospital, Abu Dhabi, UAE.
Zine-Charaf Mohamed AmirDepartment of Anatomy and Pathological Cytology and Biopathology, University Hospital Center Mustapha Pacha, Algiers, Algeria.
Hicham Abdelmalek El AttarLaboratory of Cytology and Histopathology, Annasr Pathology Center, El Jadida, Morocco.
Samah Soud AlrehailyOncology Department, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Joseph Fadi ZoueinHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.ORCID 0000-0003-0078-8582
Nabih NaimHematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon.
Ameer Dhahir HameediCollege of Medicine, University of Baghdad, Baghdad, Iraq.
Manwar Abdulelah AlnaqqashDepartment of Surgery, College of Medicine, University of Baghdad, Baghdad, Iraq.
Rami Abdel Rahim MahfouzDepartment of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Sarah MasriOncology Department, Pfizer Inc, Beirut, Lebanon.
Jamil DebsOncology Department, Pfizer Inc, Beirut, Lebanon.
Taoufiq BarrouOncology Medical Department, Pfizer Inc, Former Employee, Casablanca, Morocco.
Hatem El KadiMedical Department, Pfizer Inc, Former Employee, Dubai, UAE.
Vivek SubbiahOncology Department, Sarah Cannon Research Institute (SCRI), Nashville, TN, USA.
Frederique Penault-LlorcaDepartment of Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, UMR INSERM 1240, University Clermont Auvergne, Clermont-Ferrand, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer-related death and the second most common cancer worldwide. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases. In the Middle East and North Africa (MENA) region, lung cancer ranks second in incidence and cancer mortality, with a five-year survival rate of about 8%. To address this pressing health challenge, this expert consensus aims to provide regionally tailored recommendations to improve outcomes for patients with advanced NSCLC in the MENA region. A panel of 15 regional experts convened to develop evidence-informed guidance using a modified Delphi process. Through this structured and collaborative approach, the panel formulated 40 consensus statements covering key areas such as epidemiology, diagnostic workup, molecular testing, and the use of targeted therapies in advanced NSCLC. These statements reflect both global best practices and region-specific considerations, including access to testing and treatment. The resulting recommendations offer the first regionally adapted framework for the management of advanced NSCLC in the MENA region. By unifying clinical practice and promoting precision medicine, these guidelines aim to support clinicians in improving patient care and outcomes across the region.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsPrecision MedicineAfrica, NorthernDisease ManagementHumansMiddle EastMolecular Targeted TherapyNeoplasm StagingconsensusLung cancerMENANSCLC

Identifiers

PMID40577077
PMCPMC12323432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.